[]Fluoro-2-Deoxy-D-Glucose Incorporation by MCF-7 Breast Tumour Cells In Vitro Is Modulated by Treatment with Tamoxifen, Doxorubicin, and Docetaxel: Relationship to Chemotherapy-Induced Changes in ATP Content, Hexokinase Activity, and Glucose Transport
Open Access
- 26 October 2010
- journal article
- research article
- Published by Hindawi Limited in International Journal of Molecular Imaging
- Vol. 2011, 1-8
- https://doi.org/10.1155/2011/874585
Abstract
Breast tumours responding to chemotherapy exhibit decreased [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) incorporation. Underlying mechanisms of these changes is poorly understood. Here, in MCF-7 cells, responding to chemotherapy drugs commonly utilised in the treatment of breast cancer, [18F]FDG incorporation and several pivotal factors associated with [18F]FDG incorporation investigated. Methods. IC50 and subclinical doxorubicin, docetaxel, and tamoxifen doses determined using MTT assay. [18F]FDG incorporation by cells treated with IC50 drug doses for 48 hours and 72 hours were determined and FDG dephosphorylation estimated by measuring loss of 18F from [18F]FDG-preincubated cells (pulse-chase). Glucose transport determined by measuring initial uptake rate of non-metabolised glucose analogue omethylglucose; hexokinase activity and ATP content measured in cell homogenates; Cell cycle distribution determined using flow cytometry of propidium iodide stained nuclei. Results. [18F]FDG incorporation and ATP content decreased in cells after 72 hours treatment with IC50 doses of tamoxifen, doxorubicin, and docetaxel compared with untreated controls. Decreased glucose transport and/or hexokinase activity accompanied decreased [18F]FDG incorporation by MCF-7 cells treated with tamoxifen or doxorubicin but not docetaxel. Conclusions. Tumour cell [18F]FDG incorporation along with ATP content decreased by treatment with tamoxifen, doxorubicin and docetaxel paralleling clinical observations for solid tumours. Effect of each treatment on glucose transport and hexokinase activity was chemotherapy-drug dependent.Keywords
This publication has 27 references indexed in Scilit:
- Changes to Adjuvant Systemic Therapy in Breast Cancer: A Decade in ReviewClinical Breast Cancer, 2010
- Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro.2006
- Monitoring primary breast cancer throughout chemotherapy using FDG-PETBreast Cancer Research and Treatment, 2006
- Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent dataJournal of Surgical Oncology, 2006
- Controversies in the Therapy of Early Stage Breast CancerThe Oncologist, 2005
- Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.2005
- Measuring response to chemotherapy in locally advanced breast cancer: methodological considerationsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast CancerJournal of Clinical Oncology, 2001
- Facilitative glucose transporter expression in human cancer tissue.1999
- Tamoxifen and risk of idiopathic venous thromboembolismBritish Journal of Clinical Pharmacology, 1998